A New Approach to Cancer Immunotherapy - 主页-福 ….pptVIP

A New Approach to Cancer Immunotherapy肿瘤免疫治疗的新思路斯坦福大学医学院外科宗康拉;1) Slower tumor growth (抑制 90%) 2) Tumors shrink (肿瘤体积减小,少见) 3) Tumors disappear (治愈, 极少);32-day MCA207 before treatment;One week after Cy+IL-12;Two weeks after Cy+IL-12;Three weeks after Cy+IL-12;Four weeks after Cy+IL-12;Five weeks after Cy+IL-12;Six weeks after Cy+IL-12;Potentiation of Cy-induced Cancer Regression by IL-12通过白介素12提高化疗的抗肿瘤效果;Day-18 peritoneal MCA207 tumors 18天腹腔实体MCA207肿瘤 ;Day-14 experimental lung metastases 14天静脉注射建立的肺扩散肿瘤模型;Antitumor effects of Cy+IL-12 in MCA207 i.p. and i.v. models Cy+IL-12在腹腔及肺扩散肿瘤模型中的治疗效果;Effects of IL-12 and Cy+IL-12 in the Sa1 ascites tumor modelIL-12和Cy+IL-12在Sa1腹水肿瘤模型中的治疗效果;The rejection induced by IL-12/Cy+IL-12 is associated with a strong T cell response 与肿瘤排斥所对应的强免疫反应;Tumor rejection is mediated by a Th1 response抗肿瘤作用需要Th1型T细胞参与;Does Cy+IL-12 work on other tumor models?环磷酰胺加白介素是否对所有肿瘤有效？;Question 问题;Does Cy+IL-12 work on other tumor models? 环磷酰胺加白介素12是否对所有肿瘤有效？;Condition#1：Pre-existing immunity条件一：预存免疫;What is pre-existing immunity?什么是预存免疫？;Experimental procedure for adoptive cell transfer体细胞转导试验步骤;Tumor-sensitized T cells are necessary for IL-12-induced tumor rejection肿瘤特异的T细胞在白介素12治疗中的关键作用 ;Ccondition #2 条件2IL-12 should be given during the early phase of recalled pre-existing immunity白介素12 最佳给药时间是在预存免疫的回放早期;Timing of IL-12 following chemotherapy白介素12 的给药最佳时期;Critical timing of IL-12 administration白介素12 给药时间的关键性;Ccondition #3 条件3chemotherapy must activate antitumor immunity 化疗必须激活一个抗肿瘤免疫反应;Chemotherapy to activate antitumor immunity?化疗引发抗肿瘤免疫反应？;Immunity is responsible for cure of small tumor by Cy chemotherapy免疫参与是环磷酰胺化疗治愈小肿瘤的必要条件;Immunity is responsible for significant large tumor regression following chemotherapy免疫参与加大环磷酰胺化疗疗效;Why can chemotherapy activate antitumor immunity?为什么化疗可以激活抗肿瘤免疫反应？Through acute antigen release and recall of pre-existing immunity通过抗原急性释放达到记忆免疫的回放If true, then increase antigen presentation at t